Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MSFT$554.19+35.02(+6.72%)BRIEF-Microsoft Rejects Multibillion-Dollar AI Deal With UK's Nscale - FT12:11:33 AM ETMSFT$554.19+35.02(+6.72%)Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:09:40 AM ETTM$205.56+6.45(+3.34%)Toyota profit surges 34%, first rise in six quarters12:02:07 AM ETC$124.58+1.89(+1.54%)UPDATE 1-Oil falls for a fourth day on expectations for lower risk of Iran war escalation11:59:47 PM ETQCOM$160.25+8.76(+5.33%)SpaceX Makes Its Biggest Move Yet Against Telecom Giants With Qualcomm 5G Deal: Elon Musk Hails QCOM's Technology, Calls It 'Excellent'11:59:02 PM ETMCD$278.93+17.15(+6.52%)McDonald's: 3 Key Takeaways for Long-Term Investors11:46:01 PM ETQCOM$160.25+8.76(+5.33%)SpaceX Just Picked Qualcomm for Its Own 5G Network. I Still See the Stock as a Hold.11:41:01 PM ETIONQ$29.52-0.48(-1.60%)IonQ vs. SoundHound AI: Which Technology Stock Is a Better Buy for 2027?11:30:01 PM ETQCOM$160.25+8.76(+5.33%)Qualcomm Q4 Earnings Call Highlights11:27:00 PM ETAMD$485.27+4.95(+1.02%)AMD Stock Jumped After Its Report. I'd Wait for a Lower Price to Buy.11:17:01 PM ETGOOG$288.55+9.01(+3.24%)Google expands voluntary buyouts to 5 countries as AI spending fuels cost cuts11:16:50 PM ETSHOP$153.05+10.32(+7.23%)Shopify: 3 Key Takeaways for Long-Term Investors10:59:40 PM ETMCD$278.93+17.15(+6.52%)Why McDonald's Stock Popped Today10:45:31 PM ETMETA$630.20+8.87(+1.43%)Meta President Says Midterm Results Will Make Building Data Centers Harder10:11:00 PM ETPANW$348.32-2.07(-0.59%)BRIEF-Palo Alto Networks In Talks To Pay $500 Million For AI Security Startup Clutch Security - The Information9:57:31 PM ETMSFT$554.19+35.02(+6.72%)US STOCKS-Wall Street ends higher after Democrats win Congress; data center stocks tumble9:41:58 PM ETASML$1,479.73-72.05(-4.64%)ASML vs. Marvell Technology: Which Artificial Intelligence Stock Is a Better Buy Going into 2027?9:33:56 PM ETABT$115.40+6.10(+5.58%)DIARY-India economic, corporate events on November 59:00:32 PM ETNVO$41.87+1.67(+4.15%)Novo Nordisk: 3 Key Takeaways for Long-Term Investors8:55:55 PM ETAAPL$350.78+17.87(+5.39%)Apple is reportedly cutting budgets for its internal AI usage8:26:22 PM ETMRVL$156.78-15.14(-8.81%)Is Broadcom Stock a Buy After Marvell's $115 Billion Deal?8:23:01 PM ETARM$188.47-10.88(-5.37%)What ARM (ARM) Said on Its Q2 Earnings Call8:14:33 PM ETQCOM$160.25+8.76(+5.33%)QUALCOMM Incorporated (QCOM) Q4 2026 Earnings Call Transcript8:04:42 PM ETAMZN$265.26+15.25(+6.08%)MEDIA-Amazon’s Zoox plans to start testing in Europe and Asia - WSJ7:48:31 PM ET

CYTK · NASDAQ

Cytokinetics, Incorporated

$64.00 +1.90 (+3.05%)

Company overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$8.9B
Employees
673
Headquarters
South San Francisco, CA
Website
cytokinetics.com
CEO
Robert I. Blum
Listed
April 26, 2004
P/E
-9.37
Dividend yield
0.00%

Company financials

Revenue
$106M
Gross profit
$95.6M
Operating income
-$640M
EBITDA
-$746M
Net income
-$830M
EPS
-$6.83
Total assets
$1.3B
Total debt
$1B
Gross margin
90.34%
Net margin
-784.02%
Earnings yield
-10.67%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

58.6466.3574.0581.7589.45
CYTK 1D NASDAQ O64.06H64.96L60.98C64.21+1.90 (+3.05%)Vol2.21M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CYTKCytokinetics, Incorporated Stock news Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript Seeking Alpha
CYTKCytokinetics, Incorporated Stock news Cytokinetics Q3 Earnings Call Highlights MarketBeat
CYTKCytokinetics, Incorporated Stock news Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates Zacks Investment Research
CYTKCytokinetics, Incorporated Stock news BRIEF-Cytokinetics Q3 Basic EPS USD -1.37 Reuters
CYTKCytokinetics, Incorporated Press release Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
CYTKCytokinetics, Incorporated Press release Cytokinetics to Participate in November Investor Conferences GlobeNewswire
CYTKCytokinetics, Incorporated Press release Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 GlobeNewswire
CYTKCytokinetics, Incorporated Stock news Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy? Zacks Investment Research
AZN Stock news Baron Health Care Fund Q3 2026 Top Contributors And Detractors Seeking Alpha
CYTKCytokinetics, Incorporated Press release Cytokinetics to Announce Third Quarter Results on November 4, 2026 GlobeNewswire
CYTKCytokinetics, Incorporated Press release Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
CYTKCytokinetics, Incorporated Stock news Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth? Zacks Investment Research
CYTKCytokinetics, Incorporated Press release Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
CYTKCytokinetics, Incorporated Press release Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026 GlobeNewswire
CYTKCytokinetics, Incorporated Stock news Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK) Defense World
CYTKCytokinetics, Incorporated Press release Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026 GlobeNewswire
CYTKCytokinetics, Incorporated Stock news Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
CYTKCytokinetics, Incorporated Stock news Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference MarketBeat
CYTKCytokinetics, Incorporated Press release Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
CYTKCytokinetics, Incorporated Stock news Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
See more
FAQ

Questions about Cytokinetics, Incorporated

What does Cytokinetics, Incorporated do?
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.
What is CYTK's market cap?
Cytokinetics, Incorporated (CYTK) is a listed stock with a live quote. The latest market cap on this page is $8.9B.
Where is Cytokinetics, Incorporated headquartered?
Cytokinetics, Incorporated is headquartered in South San Francisco, CA.
How do I get CYTK news from the API?
Call GET /v1/news?tickers=CYTK. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CYTK news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CYTK, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CYTK price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs